Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;3(1):2.
doi: 10.1007/s40800-016-0025-9.

Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature

ZhuYing Cai  1 , Wei Yang  1 , YingYing He  1 , Qingge Chen  1 , ShiQiang Wang  1 , Xuming Luo  1 , Xiongbiao Wang  2
Affiliations

Cefoperazone/Sulbactam-Induced Abdominal Wall Hematoma and Upper Gastrointestinal Bleeding: A Case Report and Review of the Literature

ZhuYing Cai et al. Drug Saf Case Rep. 2016 Dec.

Abstract

An 87-year-old woman developed abdominal wall hematoma and upper gastrointestinal bleeding during treatment with cefoperazone/sulbactam for pneumonia. The woman received cefoperazone/sulbactam at 4.5 g twice daily for intravenous infusion. After 7 days, she developed sudden onset of left lower abdominal pain, associated with subcutaneous mass, and vomited a coffee-colored liquid. Investigations revealed a coagulation index abnormality and activated partial thromboplastin time and prothrombin time increased obviously. She was diagnosed with cefoperazone-induced hemorrhage. Cefoperazone/sulbactam was discontinued and the patient received vitamin K1. The blood coagulation function improved and hematoma disappeared after 3 days. A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's coagulation function disorder and her use of the suspect drug.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical Standards Conflicts of interest ZhuYin Cai, Wei Yang, YingYing He, Qingge Chen, ShiQiang Wang, Xuming Luo and Xiongbiao Wang declare that they have no conflict of interest. Consent Written informed consent was obtained from the patient for publication of this case report and the accompanying images. A copy of the written consent may be requested for review from the corresponding author.

Figures

Fig. 1
Fig. 1
a Hematoma at lower left abdominal wall was suggested by abdominal CT. b Mixed masses at left lower abdominal wall was revealed by the abdomen B ultrasound. c Absorbed hematoma by B ultrasound
See this image and copyright information in PMC

References

    1. Cohen MS, Washton HE, Barranco SF. Multicenter clinical trial of cefoperazone sodium in the United States. Am J Med. 1984;77(1B):35–41. doi: 10.1016/S0002-9343(84)80094-7. - DOI - PubMed
    1. Bailey RR, Peddie B, Blake E, Bishop V, Reddy J. Cefoperazone in the treatment of severe or complicated infections. Drugs. 1981;22(Suppl 1):76–86. doi: 10.2165/00003495-198100221-00017. - DOI - PubMed
    1. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201. doi: 10.1128/CMR.00037-09. - DOI - PMC - PubMed
    1. Greenberg RN, Reilly PM, Weinandt WJ, Bollinger M, Kennedy DJ. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation. Clin Ther. 1987;10(1):52–56. - PubMed
    1. Koga H, Tomono K, Hirakata Y, Kohno S, Abe K, Kawamoto S, et al. Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase. Jpn J Antibiot. 1996;49(8):800–807. - PubMed

LinkOut - more resources